Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Contract Signed with global IT leader ICT

14 Jul 2014 07:00

RNS Number : 1677M
Advanced Oncotherapy PLC
14 July 2014
 



 

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

 

Contract Signed with global IT leader ICT

 

Advanced Oncotherapy (AIM: AVO), the developer of the next generation of particle therapy with protons for cancer treatment, announces that they have contracted global technology leader ICT Automatisering ("ICT") to develop the software systems to manage patient workflow by the proprietary LIGHT accelerator.

 

The work flow for delivering cost effective proton beam therapy requires an integrated approach of all processes - from the first patient consultation to final day of treatment - to deliver the optimal treatment in each session.

 

With the acquisition of ADAM, a spin-off of CERN, Advanced Oncotherapy has developed the LIGHT accelerator to produce a high energy proton beam system in a most economical, efficient and cost-effective manner. The aim is to integrate the LIGHT accelerator within a fully-operational treatment facility including detailed data and process management to achieve the highest level of operational efficiency. This is achieved through tight integration of software and hardware solutions to ensure optimal interoperability.

 

AVO chose ICT after an extensive review because of their expertise in medical software standards, their domain knowledge in radiation therapy and their broad expertise in parallel industries.

 

AVO's Product Development team lead, Dr Hanne Kooy, Associate Professor of Medicine at Massachusetts General Hospital and Harvard Medical School, commented: "ICT's extensive experience with work flow architecture ensures full utilisation of the unique LIGHT characteristics to maximise patient treatment outcomes."

 

Based in the Netherlands, ICT Automatisering provides high-quality IT solutions in information and communication technology, with a particular focus on Automotive, Machine & Systems, Industrial Automation, Logistics, Energy and Healthcare. ICT has an annual turnover of nearly €80m works across Europe in the Netherlands, Germany and Poland and employs approximately 750 highly qualified personnel.

 

Jan-Willem Doosje, Business Development Manager ICT Automatisering, commented: "We are proud to advise AVO on the complex infrastructure which is needed for the integration of their LIGHT accelerator in the radiation oncology department. Our experiences gained in applying the standards in Radiation Oncology such as set by DICOM and IHE-RO (Integrating the Healthcare Enterprise - Radiation Oncology) will be of added value for the design of the infrastructure needed for the Advanced Oncotherapy proton delivery solution."

 

Sanjeev Pandya, CEO of Advanced Oncotherapy, commented: "After a review of the specialist companies working in this area, we have chosen ICT because of their commercial expertise and their close working relationship with the authorities who review and regulate the use of radiation therapies. This is another significant step towards achieving our goal of delivering and installing our first LIGHT system at the beginning of 2016."

 

 

 

 

 

For further information contact:

 

Advanced Oncotherapy Plc

Sanjeev Pandya (CEO)

www.avoplc.com

Tel: +44 20 3617 8739

 

Westhouse Securities (Nomad & Joint Broker)

Tel: +44 (0)20 7601 6100

Antonio Bossi / David Coaten

Peterhouse Corporate Finance (Joint Broker)

Tel: +44 20 7469 0930

Lucy Williams

Walbrook PR (Financial PR & IR)

avo@walbrookpr.com

Anna Dunphy / Mike Wort

 

Tel: +44 20 7933 8780

 

About Advanced Oncotherapy Plc

 

AVO's team based at CERN near Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

AVO is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, the Company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology which is proven to bring better health outcomes and lower treatment related side effects.

 

AVO continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships the Company will remain the prime provider of innovative and cost-effective equipment for proton radiation. This will allow healthcare suppliers to access more cost effective and more efficient ways to treat the increasing number of cancer patients who expect lower short term and long term side effects of their cancer care. 

 

For more information, please visit http://www.avoplc.com

 

About ICT Automatisering

ICT Automatisering's goal is to simplify and improve our clients' business, production and communication processes and to make them more flexible. We do this by using our high-grade technological expertise. We deploy this expertise in the form of inventive and effective product and market combinations. ICT is organised in line with the markets we serve. We have six verticals: Automotive, Industrial Automation, Logistics, Machine & Systems, Healthcare and Energy. Within each vertical professionals offer specific know-how and expertise of their market's products and processes. For more detailed information on ICT, visit our website at www.ict.eu.

 

 

 

About ICT's Healthcare domain

In the Healthcare domain ICT has 35 years of experience in linking systems under the header interoperability / Medical Data Exchange. The number of ICT engineers in this area has increased over the years, and the company combined their expertise in the Healthcare vertical. Their expertise goes way beyond technology nowadays, as it now also covers sector and broad and extensive domain know-how. Initially, ICT's operating domain was the hospitals/institutions in general. Nowadays ICT Healthcare focuses more specifically on medical data exchange within medical software development, and with a specialization in the 'niche' market of radiation therapy. Radiotherapy is a niche market with few active providers and a market in which customized solutions are virtually unheard of. ICT has made a strategic choice to focus its Medical Data Exchange-related efforts on the fields of radiation therapy and big data domains such as (digital) pathology. ICT has multiple customers in the radiation therapy domain varying from companies, institutions to standardization committees.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUOUNRSUABAAR
Date   Source Headline
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility
1st Mar 20232:54 pmRNSSecured Convertible Note Facility & other matters
1st Mar 20232:05 pmRNSSecond Price Monitoring Extn
1st Mar 20232:00 pmRNSPrice Monitoring Extension
27th Jan 20234:53 pmEQSHardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date
18th Jan 20232:00 pmRNSOperational update
17th Jan 20233:10 pmEQSHardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV
30th Dec 20221:00 pmRNSTotal Voting Rights
30th Dec 20229:24 amRNSDirector/PDMR Shareholding
29th Dec 20223:12 pmRNSDirector/PDMR Shareholding
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 202212:40 pmRNSSecond Price Monitoring Extn
23rd Dec 202212:35 pmRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSEquity Subscription and Issue of Warrants
1st Dec 20227:00 amRNSIssue of Equity
28th Nov 20227:00 amRNSStudy showcases the potential superiority of LIGHT
3rd Nov 20223:20 pmRNSInvestor / Analyst Event Update
31st Oct 20225:00 pmRNSTotal Voting Rights
27th Oct 20227:31 amRNSPresentation highlights superiority of LIGHT
21st Oct 20227:00 amRNSNotice of Investor / Analyst Event
18th Oct 20227:00 amRNSEquity Subscription and Issue of Warrants
30th Sep 20225:00 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSInterim Results
29th Sep 20227:15 amEQSHardman & Co Research on Advanced Oncotherapy: Major milestone achieved
27th Sep 202210:30 amRNSLIGHT accelerator fully operational
31st Aug 20225:00 pmRNSTotal Voting Rights
23rd Aug 20223:09 pmRNSUpdate re admission of Subscription Shares
19th Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
17th Aug 20225:30 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
29th Jul 20224:30 pmRNSResult of AGM
7th Jul 202212:30 pmRNSHolding(s) in Company
30th Jun 20225:00 pmRNSTotal Voting Rights
30th Jun 20229:00 amRNSFinal results for the year ended 31 December 2021
28th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
13th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
31st May 20225:00 pmRNSTotal Voting Rights
27th May 202212:17 pmRNSHolding(s) in Company
11th May 20227:00 amRNSLIGHT system potential in delivering FLASH
29th Apr 20225:00 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNSVideo showcases progress on LIGHT system process
26th Apr 20227:00 amRNSOperational update
22nd Apr 20227:00 amRNSUpdate re admission of Subscription Shares
19th Apr 20224:05 pmRNSUpdate re admission of Subscription Shares
12th Apr 20227:13 amRNSEquity Subscription and Issue of Warrants
31st Mar 20225:00 pmRNSTotal Voting Rights
25th Mar 20229:30 amRNS£2m Subscription, Add'l Loan and Issue of Warrants
14th Mar 20227:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO) - LIGHT: regulatory update
4th Mar 20229:00 amRNSDirector/PDMR Notification
3rd Mar 20226:13 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.